Join Growin Stock Community!

Immuneering corporationIMRX.US Overview

US StockHealthcare
(No presentation for IMRX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IMRX AI Insights

IMRX Overall Performance

IMRX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IMRX Recent Performance

0.60%

Immuneering corporation

0.05%

Avg of Sector

-0.31%

S&P500

IMRX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IMRX Key Information

IMRX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IMRX Profile

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Price of IMRX

IMRX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IMRX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.72
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
563.62
PB Ratio
1.42
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.72
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
563.62
PB Ratio
1.42
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is IMRX's latest earnings report released?

    The most recent financial report for Immuneering corporation (IMRX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IMRX's short-term business performance and financial health. For the latest updates on IMRX's earnings releases, visit this page regularly.

  • How much debt does IMRX have?

    As of the end of the reporting period, Immuneering corporation (IMRX) had total debt of 3.92M, with a debt ratio of 0.02. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IMRX have?

    At the end of the period, Immuneering corporation (IMRX) held Total Cash and Cash Equivalents of 227.56M, accounting for 0.94 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is IMRX's EPS continuing to grow?

    According to the past four quarterly reports, Immuneering corporation (IMRX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.38. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IMRX?

    Immuneering corporation (IMRX)'s Free Cash Flow (FCF) for the period is -11.98M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 11.08% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.